Funder: [National Institutes of Health - https://www.nih.gov]
Due Dates: November 21, 2024 (final) | Rolling prior dates through 2024
Funding Amounts: Up to $250,000 direct costs/year for R61 and R33 phases; total project period up to 3 years; cost matching required for R33 phase (0.25:1 non-Federal match)
Summary: Supports early-stage development and testing of device prototypes, diagnostic assays, and research tools for heart, lung, blood, and sleep (HLBS) disorders.
Key Information: Phased R61/R33 award; clinical trials not allowed; transition to R33 contingent on milestones, cost match, and accelerator partner; strong emphasis on project management and regulatory/IP planning.